Study of a blood-filter treatment for FSGS not responding to meds
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how well a specialized blood-filter device (the LIPOSORBER® LA-15) works for people with primary FSGS—especially when standard steroid and other medicines don’t work or can’t be tolerated. It may help reduce disease activity, particularly in people with kidney function that is still moderate or in those after kidney transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nephrotic syndrome caused by primary FSGS
- Your steroid and/or other standard medicines failed or caused problems you couldn’t tolerate, OR you’ve had a kidney transplant
- Your kidney filtration is at least 45 (GFR) OR you are post–kidney transplant
- You’re between 22 and 75 years old, and you weigh at least 15 kg (33 lbs)
- You can give consent and follow all study visits and instructions
- You’re not pregnant or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
This trial tests an investigational drug called praliciguat for people with FSGS, a kidney disease that causes scarring in the kidney filters. The goal is to see if praliciguat can help reduce protein in the urine and protect kidney function.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
This trial tests whether the diabetes drug metformin can help people with a kidney disease called FSGS, by activating a cell-protecting pathway. Participants will take metformin or a placebo along with their usual steroid treatment.
This trial collects medical data and blood/urine samples from patients with minimal change disease or focal segmental glomerulosclerosis (FSGS) to better understand how the immune system damages kidney cells.
Hear when a new Focal Segmental Glomerulosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.